Abstract: The present invention relates to the field of treatment of diseases. Specifically, the present invention relates to an anti-ROR1 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding same, and methods for preparing same. The anti-ROR1 antibody or the antigen-binding fragment thereof of the present invention has high specificity and high affinity for ROR1, and can effectively bind ROR1 and mediate killing of ROR1 expression cells. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in preparation of a drug which is used for prevention and/or treatment of tumors.
Type:
Application
Filed:
February 28, 2022
Publication date:
January 18, 2024
Applicants:
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., KLUS PHARMA INC.
Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.
Type:
Application
Filed:
December 19, 2019
Publication date:
June 22, 2023
Applicants:
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., KLUS PHARMA INC.
Inventors:
Haijun TIAN, Sujun DENG, Chunxia ZHAO, Hong LI, Dengnian LIU, Hu LONG, Cheng WANG, Liang XIAO, Tongtong XUE, Jingyi WANG